secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001104659-24-028208
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist reports Q4 profit, $300M Takeda deal extends cash runway through 2027
--------------------------------------------------------------------------------

- Entered worldwide Takeda collaboration for rusfertide; $300M upfront, US profit share, opt-out up to $400M.
- Q4 net income $27.3M ($0.45 EPS) vs loss $34.2M in Q4 2022; full year loss $79M improved from $127.4M.
- Cash $341.6M; runway extended through Q4 2027 including $300M Takeda upfront.
- Earned $60M in JNJ-2113 milestones from J&J in Q4; VERIFY Phase 3 enrollment on track for Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465924028208/0001104659-24-028208-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465924028208/tm247315d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-028208

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer